DaVita Inc. (NYSE:DVA) Stock Holdings Lifted by Advisors Asset Management Inc.

Advisors Asset Management Inc. grew its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 34.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,201 shares of the company's stock after buying an additional 4,647 shares during the quarter. Advisors Asset Management Inc.'s holdings in DaVita were worth $2,984,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Harvard Management Co. Inc. bought a new stake in DaVita in the second quarter valued at about $55,115,000. KBC Group NV raised its position in shares of DaVita by 27.3% during the 3rd quarter. KBC Group NV now owns 313,519 shares of the company's stock valued at $51,395,000 after acquiring an additional 67,250 shares in the last quarter. Andra AP fonden lifted its stake in DaVita by 9.0% during the second quarter. Andra AP fonden now owns 192,300 shares of the company's stock worth $26,647,000 after purchasing an additional 15,800 shares during the last quarter. abrdn plc boosted its holdings in DaVita by 1.2% in the third quarter. abrdn plc now owns 189,065 shares of the company's stock worth $30,719,000 after purchasing an additional 2,180 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in DaVita by 1.8% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 126,071 shares of the company's stock valued at $20,667,000 after purchasing an additional 2,186 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Stock Performance

Shares of DVA traded up $1.37 during trading hours on Friday, reaching $165.51. 612,123 shares of the company's stock traded hands, compared to its average volume of 1,021,709. The firm has a market capitalization of $13.57 billion, a price-to-earnings ratio of 17.85, a P/E/G ratio of 0.93 and a beta of 0.89. The business's fifty day simple moving average is $158.31 and its two-hundred day simple moving average is $148.45. DaVita Inc. has a twelve month low of $98.26 and a twelve month high of $168.50. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm's quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.85 earnings per share. Analysts predict that DaVita Inc. will post 9.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

DVA has been the topic of a number of recent research reports. Barclays raised their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. UBS Group lifted their target price on DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. Bank of America increased their price target on DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a research report on Wednesday, August 7th. Finally, Truist Financial upped their price objective on DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research note on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $161.80.

Insider Buying and Selling at DaVita

In other DaVita news, CEO Javier Rodriguez sold 32,176 shares of the company's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68. Following the completion of the sale, the chief executive officer now directly owns 905,659 shares of the company's stock, valued at approximately $141,219,407.87. This represents a 3.43 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of DaVita stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the transaction, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. This represents a 36.48 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 156,086 shares of company stock valued at $24,807,161. 2.00% of the stock is owned by corporate insiders.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.